SCHEMBL20548558

SCHEMBL20548558

O=c1onc(Cc2c(F)cccc2Cl)n1Cc1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 5/20 0.44
GRIN2B Q13224 5/20 0.44
LMNA P02545 2/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GABRA1 P14867 3/20 0.43
GABRA5 P31644 3/20 0.43
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
P2RX7 Q99572 1/20 0.38
NPC1 O15118 1/20 0.38
GLA P06280 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30314421 1.00 GRIN1 (0.44) GRIN1GRIN2BLMNAALDH1A1L3MBTL1
SCHEMBL30314446 0.89 KCNK13 (0.40) GRIN1GRIN2BLMNAALDH1A1L3MBTL1
SCHEMBL20548637 0.89 KCNK13 (0.40) GRIN1GRIN2BLMNAALDH1A1L3MBTL1
SCHEMBL20548428 0.89 SMN1; SMN2 (0.41) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL30314437 0.89 SMN1; SMN2 (0.41) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL20548417 0.89 LMNA (0.50) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL30314418 0.89 LMNA (0.50) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL20548546 0.85 ALDH1A1 (0.50) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL20548652 0.85 ALDH1A1 (0.50) LMNAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL30314431 0.85 ALDH1A1 (0.50) LMNAALDH1A1L3MBTL1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11623919-B2 Heterocyclic P2X7 antagonists BREYE THERAPEUTICS APS (DK) 2023-04-11 US claimed
EP-3619200-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2020-03-11 EP claimed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 US claimed
WO-2018202694-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.P.A. (IT) 2018-11-08 WO claimed
EP-3398941-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2018-11-07 EP claimed
US-11623919-B2 Heterocyclic P2X7 antagonists BREYE THERAPEUTICS APS (DK) 2023-04-11 US disclosed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 US disclosed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 US disclosed
EP-3398941-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2018-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS P2RY1, P2RX1, P2RX3 GRIN1 245/4885GRIN2B 524/4885LMNA 2079/4885
US-11623919-B2 Heterocyclic P2X7 antagonists P2RY1, P2RX1, P2RX3 GRIN1 245/4885GRIN2B 524/4885LMNA 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.